Treatment of autoimmune hepatitits according to the national, international recommendations and own experience
Journal Title: Гастроентерологія - Year 2018, Vol 52, Issue 4
Abstract
Autoimmune hepatitis (AIH) is rare liver pathology, but there is the increase in the number of patients over the last years. There is no unambiguous determination or clear pathognomonic criteria of AIH. A presence of autoantibodies, hypergammaglobulinemia, characteristic morphological changes and response to immunosuppressive therapy are inherent for AIH. Immunosupressive therapy must provide the control of autoimmune process, elimination of inflammatory syndrome, fibrosis reduction, slowing down the development of cirrhosis. The first-line drugs in AIH are corticosteroids and azathioprine, more effective than placebo. Prednisolone is prescribed at a dose of 40–60 mg/day, individual dose is 0.5–1 mg/kg/day. The higher the activity of cytolysis, the larger the required dose of prednisolone. When cytolysis is reduced according to hepatic tests, the dose of prednisolone is decreased. Methylprednisolone is used more often in practice. Azathioprine is administered either immediately or 2 weeks after prednisolone at a dose 50 mg/day with a possible increase to 100 mg/day, individual dose is 1–2 mg/kg/day. Now preference is given to combination therapy with prednisolone and azathioprine. Assessment of the effectiveness of AIH treatment involves monitoring the level of aminotransferases and immunoglobulin G, their complete normalization is desirable. To evaluate fibrosis, we used liver elastography. Treatment is actually life long. The second-line drugs are mycophenolate mofetil, cyclosporine, tacrolimus, sirolimus, everolimus and other. The mycophenolate mofetil is considered most studied. The search for effective AIG therapy continues, methods of cellular, anticytokine, antifibrotic therapies are being developed. Clinical examples from own experience are presented. Treatment of AIH is a difficult process. Modern recommendations, data from the studies and accumulated experience help considerably. The choice of therapy requires individual approach, taking into account the features of clinical course and response to therapy.
Authors and Affiliations
Yu. M. Stepanov, S. V. Kosynska
Keywords
Related Articles
- EP ID EP440852
- DOI 10.22141/2308-2097.52.4.2018.154146
- Views 85
- Downloads 0
Effective Infusion Therapy of Drug-Induced Liver and Pancreas Injuries in Patients with Pulmonary Tuberculosis
The authors examined 328 patients with pulmonary tuberculosis who had drug-induced hepatitis and drug-induced pancreatitis due to polychemotherapy. Patients had metabolic intoxication syndrome associated with increasing...
Clinical and Pathogenetic Aspects of Chronic Pancreatitis of Biliary Genesis and Obesity
The article presents an analysis of the literature data on the connection of chronic pancreatitis of biliary genesis and obesity. The obesity is associated with hormonal disorders with excessive production of hormones wi...
Evaluating the risk factors for liver injury in patients with chronic lymphocytic leukemia in the dynamics of chemotherapy
Background. B-cell chronic lymphocytic leukemia (B-CLL) treatment is accompanied by a risk of liver injury due to factors that depend on the characteristics of the patient, tumor, and chemotherapy (CT). The purpose was t...
Past, present and future of surgical treatment of peptic ulcer (50-year experience of the institute)
The article presents the literature data and the results of the author’s own research on the development of peptic ulcer surgery in the historical aspect. It is shown that the evolution of the knowledge about the etiopat...
Characteristics of the gut microbiota and the content of short-chain fatty acids in patients with irritable bowel syndrome
The article presents the issues related to gut microbiota and short-chain fatty acids in patients with irritable bowel syndrome. It was found that the faecal concentration of acetic, propionic, butyric acids is higher in...